CBIO
Crescent Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.88
+2.35%2
Insider buys (3m)
7
Insider sells (3m)
$11.1M
Net value (3m)
+17.8%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jul 20, 2026 | Fairmount Funds Management LLC · director, 10 percent owner: | Purchase | 525,897 | $0.00 |
| Jul 20, 2026 | Fairmount Funds Management LLC · director, 10 percent owner: | Purchase | 853,450 | $15 |
| Jun 23, 2026 | Brumm Joshua T · director, officer: Chief Executive Officer | Sale | 42,305 | $18 |
| Jun 23, 2026 | McNeill Jonathan · officer: President and COO | Sale | 20,549 | $18 |
| Jun 23, 2026 | Im Ellie Eunkyung · officer: Chief Medical Officer | Sale | 1,219 | $18 |
| Jun 23, 2026 | Bispham Barbara Harlin · officer: See Remarks | Sale | 1,218 | $18 |
| Jun 23, 2026 | Scalzo Richard William · officer: Chief Financial Officer | Sale | 1,112 | $18 |
| Jun 23, 2026 | Pinkas Jan · officer: Chief Scientific Officer | Sale | 1,288 | $18 |
| Jun 23, 2026 | Lynch Ryan · officer: See Remarks | Sale | 465 | $18 |
| Jun 3, 2026 | Fairmount Funds Management LLC · director, 10 percent owner: | A-Award | 11,050 | $17 |
| Jun 3, 2026 | Moran Susan · director | A-Award | 11,050 | $17 |
| Jun 3, 2026 | Violin Jonathan · director | A-Award | 11,050 | $17 |
| Jun 3, 2026 | Balcom Alexandra · director | A-Award | 11,050 | $17 |
| Jun 3, 2026 | Lubner David Charles · director | A-Award | 11,050 | $17 |
| Dec 17, 2025 | McNeill Jonathan · officer: President and COO | A-Award | 78,029 | $13 |
| Dec 17, 2025 | Im Ellie Eunkyung · officer: Chief Medical Officer | A-Award | 65,190 | $13 |
| Dec 17, 2025 | Im Ellie Eunkyung · officer: Chief Medical Officer | A-Award | 5,000 | $0.00 |
| Dec 17, 2025 | Im Ellie Eunkyung · officer: Chief Medical Officer | A-Award | 16,298 | $0.00 |
| Dec 17, 2025 | Lynch Ryan · officer: See Remarks | A-Award | 33,512 | $13 |
| Dec 17, 2025 | Lynch Ryan · officer: See Remarks | A-Award | 4,000 | $0.00 |
| Dec 17, 2025 | Lynch Ryan · officer: See Remarks | A-Award | 8,378 | $0.00 |
| Dec 17, 2025 | Bispham Barbara Harlin · officer: See Remarks | A-Award | 72,185 | $13 |
| Dec 17, 2025 | Bispham Barbara Harlin · officer: See Remarks | A-Award | 6,000 | $0.00 |
| Dec 17, 2025 | Bispham Barbara Harlin · officer: See Remarks | A-Award | 12,422 | $0.00 |
| Dec 17, 2025 | Pinkas Jan · officer: Chief Scientific Officer | A-Award | 17,507 | $0.00 |
| Dec 17, 2025 | Pinkas Jan · officer: Chief Scientific Officer | A-Award | 5,000 | $0.00 |
| Dec 17, 2025 | Pinkas Jan · officer: Chief Scientific Officer | A-Award | 70,025 | $13 |
| Dec 17, 2025 | Doughty Christopher Grant · officer: Chief Business Officer | A-Award | 8,000 | $0.00 |
| Dec 17, 2025 | Doughty Christopher Grant · officer: Chief Business Officer | A-Award | 58,855 | $13 |
| Dec 17, 2025 | Doughty Christopher Grant · officer: Chief Business Officer | A-Award | 14,714 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 17Increased 16Reduced 10Sold out 60
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Unchanged | 4,133,514 | May 15, 2026 |
| BVF INC/IL | Unchanged | 2,748,763 | May 15, 2026 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Unchanged | 2,747,866 | May 15, 2026 |
| VR ADVISER, LLC | Unchanged | 2,133,576 | May 15, 2026 |
| FCPM III SERVICES B.V. | Unchanged | 1,677,852 | May 15, 2026 |
| BALYASNY ASSET MANAGEMENT L.P. | Increased | 1,510,033 | May 15, 2026 |
| VESTAL POINT CAPITAL, LP | Unchanged | 1,500,000 | May 15, 2026 |
| OPALEYE MANAGEMENT INC. | Reduced | 1,312,615 | May 15, 2026 |
| TANG CAPITAL MANAGEMENT LLC | Increased | 1,160,000 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 801,395 | May 15, 2026 |
| LOGOS GLOBAL MANAGEMENT LP | Reduced | 482,500 | May 15, 2026 |
| DEEP TRACK CAPITAL, LP | Unchanged | 453,686 | May 15, 2026 |
| RTW INVESTMENTS, LP | Unchanged | 372,856 | May 15, 2026 |
| NEXTBio Capital Management LP | Unchanged | 372,856 | May 14, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 323,553 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jul 20, 2026